Mednet Logo
HomeHematology
Hematology

Hematology

Clinical discussions on blood disorders, coagulation, transfusion medicine, and hematologic malignancies.

Recent Discussions

Would involved site radiation therapy be recommended in a patient with POEMS syndrome whose myelopathy symptoms worsened after one cycle of CyBorD?

1
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · University Hospital Basel

I would swiftly treat this patient with a common schedule, for instance, 5 x 4 Gy. I do not see any risk of concurrent rituximab.

How does the CLL17 trial presented at ASH 2025 change current practice guidelines?

1
1 Answers

Mednet Member
Mednet Member
Medical Oncology · UPMC Hillman Cancer Center

The CLL17 study provides some tangential support for time-limited therapy in a subset of patients that I would consider now--those who have low-risk disease with IGHV mutated (non-3-21) and absent TP53 mutation or deletion. Here, we would expect patients to do quite well, and long-term follow-up exi...

Is there benefit to aggressively treating hemochromatosis in a patient who has already progressed to cirrhosis at the time of diagnosis?

1
2 Answers

Mednet Member
Mednet Member
Hematology · Oregon Health & Science University

The short answer is yes, there is a benefit to treating iron overload in a patient with hereditary hemochromatosis (HH) with cirrhosis. HH involves at least five mutations, most commonly in the HFE gene (common variants include C282Y and H63D), leading to hyperabsorption of iron and progressive accu...

For primary CNS lymphoma, when do you refer for whole brain radiation therapy (WBRT)?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · Brigham and Women's Hospital

When data are limited, consensus guidelines tend to rely on the personal clinical experiences of the guideline committee members. That may explain the NCCN guidelines. Recently, remarkable progress has been noted in the treatment of CNS lymphoma with drugs alone. Ibrutinib is particularly effective ...

How would you approach a referral for concern for hemochromatosis with ferritin elevation but otherwise normal iron studies?

1 Answers

Mednet Member
Mednet Member
Hepatology · Keck School of Medicine of USC

Interesting questions, but lack of specifics about the degree of elevation and what constitutes normal iron studies makes it difficult to directly answer this question. However, there are well-recognized causes of elevated ferritin due to non-iron overloaded conditions, including increased apoferrit...

How would you approach the management of a patient with elevated iron saturation (60%) and ferritin (500s) with negative genetic testing for hemochromatosis?

1 Answers

Mednet Member
Mednet Member
Hepatology · Northwestern Memorial Hospital

I would approach this clinical scenario in the following manner: Always starting with good medical and family history first. Is there any history compatible with secondary hemochromatosis (i.e., history of blood or multiple iron transfusions)? Could the patient be tested for other non-282Y genetic ...

What is your treatment approach for MAG antibody associated polyneuropathy?

2
1 Answers

Mednet Member
Mednet Member
Neurology · Brown University

When patients have a classic Distal acquired demyelinating sensory (DADS) Neuropathy phenotype (by clinical +/- EDX criteria), typically an SPEP/IFE is checked first, and if an IgM monoclonal gammopathy is observed, then I typically check MAG antibodies at that point (if clinical and EDX features ar...

When treating a patient with classic early stage diffuse large B-cell lymphoma (Stage I/II), when is it appropriate for patients to receive 3 versus 6 cycles of R-CHOP chemotherapy when the treatment is followed by ISRT?

1
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Duke University Medical Center

The SWOG 8736 study included patients with stage I (bulky or non-bulky) and nonbulky stage II aggressive non-Hodgkin lymphomas (mostly DLBCL). Bulky was defined as a mediastinal mass >1/3 maximal chest diameter or any mass > 10 cm. Patients were randomized to 8 cycles of CHOP or 3 cycles of CHOP + R...

How do you approach imetelstat therapy in MDS patients with baseline neutropenia or thrombocytopenia?

1 Answers

Mednet Member
Mednet Member
Hematology · University of Chicago

Given the fact that the major treatment-emergent adverse events noted on the phase III IMERGE study in the imetelstat-treated arm were neutropenia (68% Grade 3+ tox) and thrombocytopenia (62% Grade 3+ tox), it makes it somewhat difficult to utilize imetelstat (Platzbecker et al., PMID 38048786) in p...

How would you manage HHT with ongoing epistaxis despite IV bevacizumab, with a history of superficial thrombosis?

2 Answers

Mednet Member
Mednet Member
Pulmonology · University of Colorado Health

This is a complex situation with a complex answer, and the patient would likely benefit from establishing care at one of the 30 HHT centers of excellence for a more thorough evaluation. If the patient mentioned has only had cautery, we would consider them seeing an ENT at an HHT center of excellence...